Menu Search
Equities

Precipio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TGK:MUN

Precipio Inc

Actions
  • Price (EUR)5.90
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta1.2294
Data delayed at least 15 minutes, as of Oct 31 2024 07:07 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

  • Revenue in USD (TTM)22.80m
  • Net income in USD-1.25m
  • Incorporated1997
  • Employees54.00
  • Location
    Precipio Inc4 Science ParkNEW HAVEN 06511United StatesUSA
  • Phone+1 (203) 787-7888
  • Fax+1 (302) 655-5049
  • Websitehttps://www.precipiodx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.